The United States Patent and Trademark Office has notified CNS that they will be issued a patent on December 27th, 2022, for several unique pharmaceuticals which we believe will be useful for treating neurodegenerative diseases.
On Wednesday, November 2nd, Dr. Smith's abstract regarding alpha-synuclein seed-amplification was presented at the NEALS convention in Clearwater, Florida.
The presentation was given by one of the authors, Dr. Robert Bowser and the poster that was presented is below.
